ThomasJSchroederMD

PubMed

• 19 citations
  Unintentional injuries among youth with developmental disabilities in the United States, 2006–2007
  Ruth A. Brenner, Gitanjali Taneja, Thomas J. Schroeder, Ann Trumble, Patricia Moyer, Germaine M. Buck Louis> ;International Journal of Injury Control and Safety Promotion. 2013 Sep 11
• 95 citations
  National surveillance of emergency department visits for outpatient adverse drug events in children and adolescents.
  Adam L. Cohen, Daniel S. Budnitz, Kelly N. Weidenbach, Daniel B. Jernigan, Thomas J. Schroeder, Nadine Shehab, Daniel A. Pollock> ;The Journal of Pediatrics. 2008 Mar 1
• 162 citations
  Analysis of food-allergic and anaphylactic events in the National Electronic Injury Surveillance System
  Marianne Phelan Ross, Martine Ferguson, Debra Street, Karl C. Klontz, Thomas J. Schroeder, Stefano Luccioli> ;The Journal of Allergy and Clinical Immunology. 2008 Jan 1
• 617 citations
  National surveillance of emergency department visits for outpatient adverse drug events.
  Daniel S. Budnitz, Daniel A. Pollock, Kelly N. Weidenbach, Aaron B. Mendelsohn, Thomas J. Schroeder, Joseph L. Annest> ;JAMA. 2006 Oct 18
• Causes of renal allograft loss in black vs. white transplant recipients in the cyclosporine era.
  Valente, J. F., Hariharan, S., Peddi, V. R., Schroeder, T. J., Ogle, C. K., Alexander, J. W., First, M. R.> ;Clin Transplant. 1997 Jun
• Induction therapy with OKT3 in pediatric liver-transplant recipients.
  Ryckman, F. C., Schroeder, T. J., Pedersen, S. H., Dittrich, V. S., Balistreri, W. F.> ;Transplant Sci. 1994 Dec
• The incidence of antibody formation to OKT3 consequent to its use in organ transplantation.
  Carey, G., Lisi, P. J., Schroeder, T. J.> ;Transplantation. 1995 Jul 27
• Selection criteria for liver transplant donors.
  Schroeder, T. J., Pesce, A. J., Ryckman, F. C., Tressler, T. P., Brunson, M. E., Pedersen, S. H., Tchervenkov, J. I., Penn, I., Alexander, J. W., Balistreri, W. F.> ;J Clin Lab Anal. 1991
• Variations in serum OKT3 concentration based upon age, sex, transplanted organ, treatment regimen, and anti-OKT3 antibody status.
  Schroeder, T. J., Michael, A. T., First, M. R., Hariharan, S., Bhat, G., Hanto, D. W., Ryckman, F. C., Balistreri, W. F.> ;Ther Drug Monit. 1994 Aug
• Soluble interleukin-2 receptor monitoring during bacterial and viral infections in liver transplant recipients: a comparative evaluation.
  Rossi, S. J., Schroeder, T. J., Muth, K. L., Hanto, D. W., Balistreri, W. F., Ryckman, F. C.> ;Clin Transplant. 1994 Oct
• Efficacy Endpoints Conference on Acute Rejection in Kidney Transplantation: summary report of the database.
  Schroeder, T. J., Moore, L. W.> ;Am J Kidney Dis. 1998 Jun
• The US compassionate experience with thymoglobulin for the treatment of resistant acute rejection.
  Daoud, A. J., Schroeder, T. J., Kano, J., Horn, H. R., Moran, H. B., First, M. R.> ;Transplant Proc. 1997 Nov
• 26 citations
  Estimates of medical device--associated adverse events from emergency departments.
  Brockton J. Hefflin, Thomas P. Gross, Thomas J. Schroeder> ;American Journal of Preventive Medicine. 2004 Oct 1
• Join now to see all